Grünenthal GmbH: Acute Pain trials

The registry lists 11 Acute Pain studies with Grünenthal GmbH as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 1 5Phase 2 3Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Trial of GRT7040 in Adults With Acute Pain Following BunionectomyNot yet recruitingNCT07807644Phase 2
• Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar ExtractionCompletedNCT03714672Phase 3Results posted
• A Study to Look at Tapentadol Oral Solution in Children and Adolescents in PainCompletedNCT02081391Phase 3Results posted
• Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative PainCompletedNCT01729728Phase 2Results posted
• Intravenous Tapentadol in Post-Bunionectomy PainCompletedNCT01435577Phase 2Results posted
• A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After BunionectomyCompletedNCT00609466Phase 3Results posted
• A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be AbusedCompletedNCT03768024Phase 1
• A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure to Investigate the Safety and Tolerability of GRT0151Y and to Find Out Which Single Dose of the Compound is Maximally ToleratedCompletedNCT03765658Phase 1
• A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the BodyCompletedNCT03761407Phase 1
• A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy AdultsWithdrawnNCT03137030Phase 1
• A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy AdultsWithdrawnNCT03137017Phase 1